Partner with us

Trusted Depression Care for Your Patients

Whether you're exploring a new referral partnership or looking for additional information about our services, our team is here to help.


Complete the form, and a member of our provider relations team will reach out to answer your questions, discuss your referral needs, and provide the information you need to determine whether our services are the right fit for your patients.

Request More Information

The information provided is subject to the Greenbrook Privacy Policy

We're Changing the Way Depression is Treated

When your patients need advanced treatment for depression or OCD, you need a referral partner you can trust. Greenbrook Mental Wellness Centers is a leading provider of advanced mental health treatments, specializing in access to care for adults and adolescents with depression and adults with OCD who have not found relief through traditional medications. With 60,000 patients treated1 and over a decade of experience, our clinical expertise in delivering NeuroStar®  TMS and SPRAVATO®  (esketamine) nasal spray sets us apart.


We partner closely with healthcare professionals to ensure patients receive timely and appropriate care. Every referral is treated with urgency, compassion, and respect, so your patient receives the best care. From streamlined intake to ongoing communication throughout treatment, our team is committed to making the referral process seamless while keeping you informed.

Why refer to us?

We are committed to supporting both patients and referring providers through:

  • Evidence-based depression treatment options
  • Collaborative communication with referring providers
  • Individualized treatment planning for your patient
  • A patient-centered approach focused on long-term outcomes
  • Streamlined referral and patient outreach process

our services

Greenbrook’s Advanced Treatment Options

NeuroStar TMS Therapy

A non-drug, FDA-cleared treatment that uses targeted magnetic pulses to stimulate specific areas of the brain associated with mood regulation, ideal for patients unresponsive to traditional therapies. In a real-world clinical study, 83% of patients responded to an acute course of NeuroStar, and 62% achieved remission.7

SPRAVATO®

FDA-approved for treatment-resistant depression, esketamine nasal spray treatment is a novel approach that provides rapid symptom relief by targeting NMDA receptors, often effective within weeks.2,3 69% of patients responded to SPRAVATO® + Oral AD and 52% achieved remission.17